Neumora Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(unaudited, in thousands)
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2025 | 174,260 | $17 | $1,288,003 | $(1,184,149) | $103,871 |
| Issuance of common stock through at-the-market transactions net of offering costs of $0.2 million | 5,343 | 1 | 10,874 | — | 10,875 |
| Vesting of restricted stock units | 218 | — | — | — | — |
| Issuance of common stock upon conversion of convertible debt | 2,336 | — | 1,987 | — | 1,987 |
| Stock-based compensation | — | — | 7,405 | — | 7,405 |
| Net loss | — | — | — | (53,458) | (53,458) |
| Balance as of March 31, 2026 | 182,157 | $18 | $1,308,269 | $(1,237,607) | $70,680 |
| Issuance of common stock through at-the-market transactions net of offering costs of $0.2 million | 4,542 | 1 | 9,497 | — | 9,498 |
| Issuance of common stock under employee stock purchase plan | 152 | — | 239 | — | 239 |
| Stock-based compensation | — | — | 7,184 | — | 7,184 |
| Net loss | — | — | — | (43,082) | (43,082) |
| Balance as of June 30, 2026 | 186,851 | $19 | $1,325,189 | $(1,280,689) | $44,519 |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2024 | 161,710 | $16 | $1,234,207 | $62 | $(947,221) | $287,064 |
| Forfeiture of unvested restricted common stock | (231) | — | — | — | — | — |
| Vesting of restricted stock units | 269 | — | — | — | — | — |
| Vesting of common stock subject to repurchase | — | — | 33 | — | — | 33 |
| Unrealized loss on marketable debt securities | — | — | — | (65) | — | (65) |
| Stock-based compensation | — | — | 9,324 | — | — | 9,324 |
| Net loss | — | — | — | — | (67,992) | (67,992) |
| Balance as of March 31, 2025 | 161,748 | $16 | $1,243,564 | $(3) | $(1,015,213) | $228,364 |
| Issuance of common stock under employee stock purchase plan | 97 | — | 59 | — | — | 59 |
| Vesting of restricted stock units | 102 | — | — | — | — | — |
| Vesting of common stock subject to repurchase | — | — | 34 | — | — | 34 |
| Unrealized loss on marketable debt securities | — | — | — | (12) | — | (12) |
| Stock-based compensation | — | — | 7,165 | — | — | 7,165 |
| Net loss | — | — | — | — | (52,731) | (52,731) |
| Balance as of June 30, 2025 | 161,947 | $16 | $1,250,822 | $(15) | $(1,067,944) | $182,879 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.